Stryker Corporation $SYK Stock: Generali Investments Management Co LLC Reduces Holdings

Key Points

• Generali Investments Management reduced its Stryker stake by 32.8% in the third quarter, selling 3,473 shares and retaining 7,102 shares valued at approximately $1.96 million.
• Despite the reduction, other institutions established or expanded positions, and institutional investors collectively own 77.09% of Stryker. Insiders have also sold roughly 351,267 shares worth $118.2 million over the past three months.
• Wall Street maintains a “Moderate Buy” consensus with an average price target of $369, while Stryker recently exceeded quarterly earnings expectations and announced a quarterly dividend of $0.88 per share.

Generali Investments Management Co LLC cut its position in shares of Stryker Corporation (NYSE:SYK - Free Report) by 32.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 7,102 shares of the medical technology company's stock after selling 3,473 shares during the quarter. Generali Investments Management Co LLC's holdings in Stryker were worth $1,956,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Gables Capital Management Inc. acquired a new position in Stryker in the second quarter valued at approximately $25,000. Kilter Group LLC bought a new stake in shares of Stryker in the 2nd quarter valued at $25,000. Highland Investment Advisors LLC bought a new stake in shares of Stryker in the 2nd quarter valued at $25,000. Cornerstone Financial Management LLC increased its stake in shares of Stryker by 66.0% in the 2nd quarter. Cornerstone Financial Management LLC now owns 78 shares of the medical technology company's stock valued at $25,000 after acquiring an additional 31 shares in the last quarter. Finally, Sankala Group LLC acquired a new position in shares of Stryker during the 4th quarter valued at $26,000. Institutional investors own 77.09% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on SYK shares. Sanford C. Bernstein restated a "market perform" rating on shares of Stryker in a report on Wednesday, October 7th. Citizens Jmp dropped their price objective on shares of Stryker from $440.00 to $400.00 and set a "market outperform" rating on the stock in a report on Monday, August 3rd. Canaccord Genuity Group cut their price objective on shares of Stryker from $400.00 to $385.00 and set a "buy" rating on the stock in a research report on Friday, September 18th. Barclays upgraded Stryker to a "strong-buy" rating in a research note on Wednesday, October 7th. Finally, Wells Fargo & Company reduced their target price on Stryker from $418.00 to $348.00 and set an "overweight" rating for the company in a research note on Wednesday, September 9th. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $369.00.

Insider Activity

In related news, insider Dylan Crotty sold 441 shares of Stryker stock in a transaction on Friday, August 21st. The shares were sold at an average price of $328.61, for a total value of $144,917.01. Following the transaction, the insider directly owned 6,102 shares of the company's stock, valued at $2,005,178.22. The trade was a 6.74% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Debra King sold 826 shares of the business's stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total transaction of $277,783.80. Following the completion of the transaction, the insider owned 6,210 shares in the company, valued at $2,088,423. The trade was a 11.74% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 351,267 shares of company stock worth $118,197,701. 4.60% of the stock is currently owned by insiders.

Stryker Trading Down 0.1%

NYSE:SYK opened at $294.33 on Monday. Stryker Corporation has a 12 month low of $267.00 and a 12 month high of $392.55. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59. The firm's 50 day moving average is $299.31 and its 200 day moving average is $312.76. The stock has a market capitalization of $112.90 billion, a PE ratio of 30.50, a price-to-earnings-growth ratio of 1.87 and a beta of 0.78.

Stryker (NYSE:SYK - Get Free Report) last posted its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, topping the consensus estimate of $3.49 by $0.20. The company had revenue of $6.59 billion during the quarter, compared to the consensus estimate of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%. The firm's quarterly revenue was up 9.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Sell-side analysts expect that Stryker Corporation will post 14.93 earnings per share for the current year.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.2%. The ex-dividend date is Wednesday, September 30th. Stryker's dividend payout ratio is presently 36.48%.

About Stryker

Stryker Corporation NYSE: SYK is a global medical technology company that develops and manufactures products used by healthcare providers in hospitals, surgical centers and other clinical settings. Its offerings are designed to support orthopaedic procedures, surgery, emergency care, neurovascular treatment and patient handling.

The company's product portfolio includes orthopaedic implants and instruments, products for trauma and spine procedures, surgical equipment, endoscopy systems, patient beds and stretchers, emergency medical equipment, and neurovascular devices used in the treatment of conditions such as stroke.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.